{{Rsnum
|rsid=12572351
|Gene=CYP2C9
|Chromosome=10
|position=96703220
|Orientation=plus
|GMAF=0.1653
|Gene_s=CYP2C9
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=135
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 27.4 | 71.7
| HCB | 8.0 | 49.6 | 42.3
| JPT | 11.5 | 46.9 | 41.6
| YRI | 0.0 | 1.4 | 98.6
| ASW | 0.0 | 1.8 | 98.2
| CHB | 8.0 | 49.6 | 42.3
| CHD | 9.2 | 34.9 | 56.0
| GIH | 12.9 | 31.7 | 55.4
| LWK | 0.9 | 5.5 | 93.6
| MEX | 1.7 | 20.7 | 77.6
| MKK | 0.0 | 9.6 | 90.4
| TSI | 2.0 | 18.6 | 79.4
| HapMapRevision=28
}}{{PMID Auto
|PMID=22321278
|Title=[Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy]
}}

{{PMID|22178823}} [Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}